The study analysed the burden of lung cancer in the Western Pacific Region (WPRO) based on Global Burden of Disease Study 2021 data for the years 1990 to 2021. In 2021, there were 1.15 million new cases (95% UI 0.96-1.36) and 0.99 million deaths (95% UI 0.82-1.16). From 1990 to 2021, the age-standardized incidence rate decreased the most in Singapore (-38.62, 95% UI -46.63 to -30.99), while it increased the most in China (32.92, 95% UI 1.21-71.31). Of the 3,889 clinical trials in the WPRO between 2010 and 2022, 24.48% of trials used patient-reported outcome (PRO) tools. The majority of these trials took place in China, Japan, Australia and South Korea. The frequently used PRO instruments were the EORTC QLQ-C30 quality of life questionnaire, the EORTC QLQ-LC13 and the visual analogue scale. There are significant differences in the burden of lung cancer between countries in the region. There is a need to allocate resources to standardized PROs and strategies to minimize the burden, especially in countries with low and intermediate SDI.